Recent advances on polaprezinc for medical use (Review)

Li,Mingru; Sun,Zhen; Zhang,Hong; Liu,Zhaoyang

doi:10.3892/etm.2021.10880

Recent advances on polaprezinc for medical use (Review)

Authors:
- Mingru Li
- Zhen Sun
- Hong Zhang
- Zhaoyang Liu
View Affiliations

Affiliations: Jilin Broadwell Pharmaceutical Co., Ltd., Liaoyuan, Jilin 136200, P.R. China, Department of Gastroenterology, Jilin People's Hospital, Jilin City, Jilin 132000, P.R. China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China
Published online on: October 14, 2021 https://doi.org/10.3892/etm.2021.10880
Article Number: 1445

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study described the chemical and biological properties of zinc complex of L‑carnosine (L‑CAZ; generic name, polaprezinc; chemical name, catena‑(S)‑[µ‑[N(α)‑(3‑aminopropionyl) histidinato (2‑) N1, N2, O: N(τ)]‑zinc], molecular formula, C₉H₁₄N₄O₃Zn; molecular weight, 291.6404; CAS registry number, 107667‑60‑7). Characterized as a white or yellowish white crystalline powder, this drug is insoluble in glacial acetic acid and almost insoluble in water, methanol, ethanol and ether. It is soluble in dilute hydrochloric acid, dilute nitric acid and sodium hydroxide solution, and its melting point is 260‑270˚C. Polaprezinc is an anti‑ulcer drug that was jointly studied and developed by Hamari Chemicals Co., Ltd. and Zeria Pharmaceutical Co., Ltd., and was first approved in Japan in 1994. This review article summarizes the research advances of polaprezinc, including the patents, preparations, synthetic routes, pharmacokinetics, pharmacological effects and application in clinical research.

View Figures

View References

1	Seiki M, Ueki S, Tanaka Y, Soeda M, Hori Y, Aita H, Yoneta T, Morita H, Tagashira E and Okabe S: Studies on anti-ulcer effects of a new compound, zinc l-carnosine (z-103). Nihon Yakurigaku Zasshi. 95:257–269. 1990.PubMed/NCBI View Article : Google Scholar : (In Japanese).
2	Tan B, Luo HQ, Xu H, Lv NH, Shi RH, Luo HS, Li JS, Ren JL, Zou YY, Li YQ, et al: Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. PLoS One. 12(e0175625)2017.PubMed/NCBI View Article : Google Scholar
3	Wada I, Otaka M, Jin M, Odashima M, Komatsu K, Konishi N, Matsuhashi T, Horikawa Y, Ohba R, Itoh H and Watanabe S: Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats-Correlation of HSP72 expression with mucosal protection. Biochem Biophys Res Commun. 349:611–618. 2006.PubMed/NCBI View Article : Google Scholar
4	Qin Y, Naito Y, Handa O, Hayashi N, Kuki A, Mizushima K, Omatsu T, Tanimura Y, Morita M, Adachi S, et al: Heat shock protein 70-dependent protective effect of polaprezinc on acetylsalicylic acid-induced apoptosis of rat intestinal epithelial cells. J Clin Biochem Nutr. 49:174–181. 2011.PubMed/NCBI View Article : Google Scholar
5	Ohkawara T, Nishihira J, Nagashima R, Takeda H and Asaka M: Polaprezinc protects human colon cells from oxidative injury induced by hydrogen peroxide: Relevant to cytoprotective heat shock proteins. World J Gastroenterol. 12:6178–6181. 2006.PubMed/NCBI View Article : Google Scholar
6	Ueda K, Ueyama T, Oka M, Ito T, Tsuruo Y and Ichinose M: Polaprezinc (Zinc L-Carnosine) is a potent inducer of anti-oxidative stress enzyme, Heme Oxygenase (HO)-1-a new mechanism of gastric mucosal protection. Pharmacol Sci. 110:285–294. 2009.PubMed/NCBI View Article : Google Scholar
7	Omatsu T, Naito Y, Handa O, Mizushima K, Hayashi N, Qin Y, Harusato A, Hirata I, Kishimoto E, Okada H, et al: Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury. J Gastroenterol. 45:692–702. 2010.PubMed/NCBI View Article : Google Scholar
8	Shimada T, Watanabe N, Ohtsuka Y, Endoh M, Kojima K, Hiraishi H and Terano A: Polaprezinc Down-regulates proinflammatory cytokine-induced nuclear Factor-kappaB activation and Interleukin-8 expression in gastric epithelial cells. J Pharmacol Exp Ther. 291:345–352. 1999.PubMed/NCBI
9	Handa O, Yoshida N, Tanaka Y, Ueda M and Yoshikawa T: Inhibitory effect of polaprezinc on the inflammatory response to Helicobacter pylori. Can J Gastroenterol. 16:785–789. 2002.PubMed/NCBI View Article : Google Scholar
10	Ohata S, Moriyama C, Yamashita A, Nishida T, Kusumoto C, Mochida S, Minami Y, Nakada J, Shomori K, Inagaki Y, et al: Polaprezinc protects mice against endotoxin shock. J Clin Biochem Nutr. 46:234–243. 2010.PubMed/NCBI View Article : Google Scholar
11	Watanabe S, Wang XE, Hirose M, Kivilioto T, Osada T, Miwa H, Oide H, Kitamura T, Yoneta T and Seto K: Insulin-like growth factor I Plays a role in gastric wound healing: Evidence using a zinc derivative, polaprezinc, and an in vitro rabbit wound repair model. Aliment Pharmacol Ther. 12:1131–1138. 1998.PubMed/NCBI View Article : Google Scholar
12	Seto K, Yoneta T, Suda H and Tamaki H: Effect of polaprezinc (N-(3-aminopropionyl)-L-histidinato zinc), a novel antiulcer agent containing zinc, on cellular proliferation: Role of insulin-like growth factor I. Biochem Pharmacol. 58:245–250. 1999.PubMed/NCBI View Article : Google Scholar
13	Jung DH, Park JC, Lee YC, Lee SK, Shin SK, Chung H, Park JJ, Kim JH, Youn YH and Park H: Comparison of the efficacy of Polaprezinc plus proton pump inhibitor and rebamipide plus proton pump inhibitor treatments for endoscopic submucosal dissection-induced ulcers. Clin Gastroenterol. 55:233–238. 2021.PubMed/NCBI View Article : Google Scholar
14	Kono T, Asama T, Chisato N, Ebisawa Y, Okayama T, Imai K, Karasaki H, Furukawa H and Yoneda M: Polaprezinc prevents ongoing thioacetamide-induced liver fibrosis in rats. Life Sci. 90:122–130. 2012.PubMed/NCBI View Article : Google Scholar
15	Katayama S, Nishizawa K, Hirano M, Yamamura S and Momose Y: Effect of polaprezinc on healing of acetic acid-induced stomatitis in hamsters. J Pharm Pharm Sci. 3:114–117. 2000.PubMed/NCBI
16	Liu Z, Xie W, Li M, Teng N, Liang X, Zhang Z, Yang Z and Wang X: Oral administration of polaprezinc attenuates fluorouracil induced intestinal mucositis in a mouse model. Basic Clin Pharmacol Toxicol. 121:480–486. 2017.PubMed/NCBI View Article : Google Scholar
17	Liu ZY, Xie WB, Li MR, Teng N, Liang X and Zhang ZQ: Effects of polaprezinc on gastric mucosal damage and neurotransmitters in a rat model of chemotherapy-induced vomiting. Int Med Res. 46:2436–2444. 2018.PubMed/NCBI View Article : Google Scholar
18	Liu ZY, Xie WB, Li MR, Liu J, Liang X and Li T: Intrarectally administered polaprezinc attenuates the development of dextran sodium sulfate-induced ulcerative colitis in mice. Exp Ther Med. 18:4927–4934. 2019.PubMed/NCBI View Article : Google Scholar
19	Kashimura H, Suzuki K, Hassan M, Ikezawa K, Sawahata T, Watanabe T, Nakahara A, Mutoh H and Tanaka N: Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxicillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther. 13:483–487. 1999.PubMed/NCBI View Article : Google Scholar
20	Nishizawa T, Suzuki H, Kanai T and Yahagi N: Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissection-induced ulcer: A systematic review and meta-analysis. J Clin Biochem Nutr. 56:85–90. 2015.PubMed/NCBI View Article : Google Scholar
21	Matsukura T and Tanaka H: Applicability of zinc complex of L-carnosine for medical use. Biochemistry (Mosc). 65:817–823. 2000.PubMed/NCBI
22	Matsuda K, Mera Y, Wada H, Aruga H, Saik Y and Taniguchi Y: Repeated dose toxicity studies on catena-(S)-[mu-[N alpha-(3-aminopropionyl) histidinato(2-)-N1,N2,O:N tau]-zinc] in rats. Arzneimittelforschung. 41(1036)1991.PubMed/NCBI
23	Furuta S, Toyama S, Miwa M and Sano H: Disposition of polaprezinc (zinc L-carnosine complex) in rat gastrointestinal tract and effect of cimetidine on its adhesion to gastric tissues. J Pharm Pharmacol. 47:632–636. 1995.PubMed/NCBI View Article : Google Scholar
24	Choi HS, Lim JY, Chun HJ, Lee M, Kim ES, Keum B, Seo YS, Jeen YT, Um SH, Lee HS, et al: The effect of polaprezinc on gastric mucosal protection in rats with ethanol induced gastric mucosal damage: Comparison study with rebamipide. Life Sci. 93:69–77. 2013.PubMed/NCBI View Article : Google Scholar
25	Fujii Y, Matsura T, Kai M, Kawasaki H and Yamada K: Protection by polaprezinc, an anti-ulcer drug, against indomethacin-induced apoptosis in rat gastric mucosal cells. Jpn J Pharmacol. 84:63–70. 2000.PubMed/NCBI View Article : Google Scholar
26	Yakoob J, Abbas Z, Jafri W, Usman MW and Awan S: Zinc chloride inhibits Helicobacter pylori growth and reduces expression of interleukin-1beta by gastric epithelial cells. Br J Biomed Sci. 71:43–45. 2014.PubMed/NCBI View Article : Google Scholar
27	Ishihara R, Iishi H, Sakai N, Yano H, Uedo N, Narahara H, Iseki K, Mikuni T, Ishiguro S and Tatsuta M: Polaprezinc attenuates Helicobacter pylori-associated gastritis in Mongolian gerbils. Helicobacter. 7:384–389. 2010.PubMed/NCBI View Article : Google Scholar
28	Naito Y, Yoshikawa T, Yagi N, Matsuyama K, Yoshida N, Seto K and Yoneta T: Effects of polaprezinc on lipid peroxidation, neutrophil accumulation, and TNF-alpha expression in rats with aspirin-induced gastric mucosal injury. Dig Dis Sci. 46:845–851. 2001.PubMed/NCBI View Article : Google Scholar
29	Aita H, Yoneta T, Seto K, Morit H, Hori Y, Takemasa T, Chaki K, Yamada H, Seiki M and Tagashira E: Studies on the healing promoting action of Z-103 in chronic gastric ulcer models of rats. Nihon Yakurigaku Zasshi. 99:345–352. 1992.PubMed/NCBI View Article : Google Scholar : (In Japanese).
30	Odashima M, Otaka M, Jin M, Wada I, Horikawa Y, Matsuhashi T, Ohba R, Hatakeyama N, Oyake J and Watanabe S: Zinc L-carnosine protects colonic mucosal injury through induction of heat shock protein 72 and suppression of NF-kappaB activation. Life Sci. 79:2245–2250. 2006.PubMed/NCBI View Article : Google Scholar
31	Ko JK and Leung CC: Ginger extract and polaprezinc exert gastroprotective actions by anti-oxidant and growth factor modulating effects in rats. J Gastroenterol Hepatol. 25:1861–1869. 2010.PubMed/NCBI View Article : Google Scholar
32	Matsuoka S, Matsumura H, Nakamura H, Oshiro S, Arakawa Y, Hayashi J, Sekine N, Nirei K, Yamagami H, Ogawa M, et al: Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis. J Clin Biochem Nutr. 45:292–303. 2009.PubMed/NCBI View Article : Google Scholar
33	Ye J, Zhang ZS, Zhu L, Lu FM, Li Y, Zhou JJ, Lu XL and Du Q: Polaprezinc inhibits liver fibrosis and proliferation in hepatocellular carcinoma. Mol Med Rep. 16:5523–5528. 2017.PubMed/NCBI View Article : Google Scholar
34	Matsumura H, Nirei K, Nakamura H, Arakawa Y, Higuchi T, Hayashi J, Yamagami H, Matsuoka S, Ogawa M, Nakajima N, et al: Zinc supplementation therapy improves the outcome of patients with chronic hepatitis C. J Clin Biochem Nutr. 51:178–184. 2012.PubMed/NCBI View Article : Google Scholar
35	Amin M, Iqbal MS, Hughes RW, Khan SA, Reynolds PA, Enne VI, Sajjad-ur-Rahman and Mirza AS: Mechanochemical synthesis and in vitro anti-Helicobacter pylori and uresase inhibitory activities of novel zinc(II)-famotidine complex. J Enzyme Inhib Med Chem. 25:383–390. 2010.PubMed/NCBI View Article : Google Scholar
36	Nishizawa T and Yahagi N: Endoscopic mucosal resection and endoscopic submucosal dissection: Technique and new directions. Curr Opin Gastroenterol. 33:315–319. 2017.PubMed/NCBI View Article : Google Scholar
37	Inaba T, Ishikawa S, Toyokawa T, Ishikawa H, Miyahara K, Wato M, Kawai K, Okada H and Yamamoto K: Basal protrusion of ulcers induced by endoscopic submucosal dissection (ESD) during treatment with proton pump inhibitors, and the suppressive effects of polaprezinc. Hepatogastroenterology. 57:678–684. 2010.PubMed/NCBI
38	Watari I, Oka S, Tanaka S, Aoyama T, Imagawa H, Shishido T, Yoshida S and Chayama K: Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: A pilot randomized controlled study. Gastroenterology. 13(108)2013.PubMed/NCBI View Article : Google Scholar
39	Doi H, Fujiwara M, Suzuki H, Niwa Y, Nakayama M, Shikata T, Odawara S, Takada Y, Kimura T, Kamikonya N and Hirota S: Polaprezinc reduces the severity of radiation-induced mucositis in head and neck cancer patients. Mol Clin Oncol. 3:381–386. 2015.PubMed/NCBI View Article : Google Scholar
40	Hayashi H, Kobayashi R, Suzuki A, Ishihara M, Nakamura N, Kitagawa J, Kanemura N, Kasahara S, Kitaichi K, Hara T, et al: Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation. Anticancer Res. 34:7271–7277. 2014.PubMed/NCBI
41	Ishihama H, Sayo S, Yokoyama T, Ueno M, Ebihara N, Doi Y, Asano K, Kawamata H, Imai H and Ueki K: P1-032preventive and therapeutic effects of Polaprezinc suspension on oral mucosal injury. Ann Oncol. 24:ix66–ix99. 2013.
42	Hayashi H, Kobayashi R, Suzuki A, Yamada Y, Ishida M, Shakui T, Kitagawa J, Hayashi H, Sugiyama T, Takeuchi H, et al: Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy. Med Oncol. 33(91)2016.PubMed/NCBI View Article : Google Scholar
43	Masayuki F, Norihiko K, Keita T, Miwa I, Masayuki I, Toshihiko I, Hiromi F, Chikaaki M and Norio N: Efficacy and safety of polaprezinc as a preventive drug for radiation-induced stomatitis. Nihon Igaku Hoshasen Gakkai Zasshi. 62:144–150. 2002.PubMed/NCBI(In Japanese).
44	Doi H, Kamikonya N, Takada Y, Fujiwara M, Tsuboi K, Inoue H, Tanooka M, Nakamura T, Shikata T, Tsujimura T and Hirota S: Efficacy of Polaprezinc for acute radiation Proctitis in a rat model. Int J Radiat Oncol Biol Phys. 80:877–884. 2011.PubMed/NCBI View Article : Google Scholar
45	Odawara S, Doi H, Shikata T, Kitajima K, Suzuki H, Niwa Y, Kosaka K, Tarutani K, Tsujimura T, Kamikonya N and Hirota S: Polaprezinc protects normal intestinal epithelium against exposure to ionizing radiation in mice. Mol Clin Oncol. 5:337–381. 2016.PubMed/NCBI View Article : Google Scholar
46	Itagaki M, Saruta M, Saijo H, Mitobe J, Arihiro S, Matsuoka M, Kato T, Ikegami M and Tajiri H: Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis. Scand J Gastroenterol. 49:164–172. 2014.PubMed/NCBI View Article : Google Scholar
47	Zhang Y, Okamura S, Kudo T, Masuo T and Mori M: Calcineurin inhibition by polaprezinc in rats with experimentally-induced colitis. Life Sci. 88:432–439. 2011.PubMed/NCBI View Article : Google Scholar
48	Hewlings S and Kalman D: A review of Zinc-L-Carnosine and its positive effects on oral Mucositis, taste disorders, and gastrointestinal disorders. Nutrients. 12(665)2020.PubMed/NCBI View Article : Google Scholar
49	Takaoka T, Sarukura N, Ueda C, Kitamura Y, Kalubi B, Toda N, Abe K, Yamamoto S and Takeda N: Effects of zinc supplementation on serum zinc concentration and ratio of apo/holo-activities of angiotensin converting enzyme in patients with taste impairment. Auris Nasus Larynx. 37:190–194. 2010.PubMed/NCBI View Article : Google Scholar
50	Mizukami Y, Sato J, Nihei S, Kashiwaba M, Kudo K, Okuyama H and Tamura K: The effectiveness of Polaprezinc preparation for taste alteration in cancer chemotherapy. Gan To Kagaku Ryoho. 43:979–983. 2016.PubMed/NCBI(In Japanese).
51	Sakagami M, Ikeda M, Tomita H, Ikui A, Aiba T, Takeda N, Inokuchi A, Kurono Y, Nakashima M, Shibasaki Y and Yotsuya O: A zinc-containing compound, Polaprezinc, is effective for patients with taste disorders: Randomized, double-blind, placebo-controlled, multi-center study. Acta Otolaryngol. 129:1115–1120. 2009.PubMed/NCBI View Article : Google Scholar
52	Kimura K, Nakano Y, Sugizaki T, Shimoda M, Kobayashi N, Kawahara M and Tanaka KI: Protective effect of polaprezinc on cadmium-induced injury of lung epithelium. Metallomics. 11:1310–1320. 2019.PubMed/NCBI View Article : Google Scholar
53	Japan standard commodity classification No. 872329: 11, 2009. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/2329027.